You are here

Article Text

Article menu
Download PDFPDF
Colorectal
Review
Colonic stents: who, where, when
  1. Hannah McCaughan,
  2. Grant Caddy,
  3. Tony C Tham
  1. Gastroenterology, Ulster Hospital, Dundonald, Belfast, Northern Ireland, UK
  1. Correspondence to Dr Tony C Tham; tctham1234{at}gmail.com

Abstract

Large bowel obstruction can be caused by advanced colonic cancer, extracolonic obstruction or benign strictures. The technical success rate of colonic stents for the treatment of colorectal obstruction is about 87% with complications or technical failure at about 14%. Mortality associated with the procedure is <4% and perforation is 4.5%. This article will discuss who would benefit from colonic stents including bridge to surgery, palliation, benign strictures and who should be performing this procedure. The insertion of stents in the colon has been primarily studied in the left colon, although proximal obstruction will also be discussed. The timing of stent insertion, in relation to symptoms and chemotherapy, will be discussed.

  • COLONIC NEOPLASMS
  • STENTS

https://doi.org/10.1136/flgastro-2024-102697

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors HM produced the initial review paper based on a presentation of the same name given by TCT at this year's BSG meeting. Various iterations and edits were then completed between TCT, HM and GC. The information used for the review was based on workplace experience from TCT and GC of colonic stent insertion, with reference to international guidelines and larger studies on colonic stent insertion to provide scientific backing for the recommendations.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; externally peer reviewed.